bioRxiv Science⌕ Search

Biology subjects

Bullen, J.

Publications and source records attributed to Bullen, J..

2 recordsLinked to original sources

Evaluating computational approaches for comparison of protein expression across cancer indications

BackgroundThe National Cancer Institutes Clinical Proteomic Tumor Analysis Consortium (CPTAC) recently generated harmonized genomic, transcriptomic, proteomic, and clinical data for over 1,000 tumors across 10 cohorts to facilitate pan-cancer discovery research. However, protein expression comparison across CPTAC cohorts remains challenging due to non-uniform missing data and varying protein expression distribution patterns across tumor types. Here, we present our efforts to evaluate various missing data handling and normalization strategies to create a normalized pan-cancer protein expression dataset. ResultsFirst, we developed a novel algorithm to select robustly expressed proteins in tumors within any CPTAC cohort. Second, we applied a cohort hybrid imputation approach to protein abundance values from FragPipe within each cohort based on protein expression distribution patterns. Third, we calculated intensity-based absolute quantification using protein abundance values and applied both global and smooth quantile normalization methods. Our results indicate that global quantile normalization ensured identical distribution across cohorts for both tumor and normal tissues, while smooth quantile normalization preserved distribution differences between biological conditions. We assessed our method by comparing differential protein expression analysis results with and without normalization. Additionally, we examined the ranks of protein expression in the normalized CPTAC dataset for selected proteins with high protein-to-RNA expression correlation across CPTAC cohorts. We then compared these protein expression ranks with their RNA expression ranks across corresponding cohorts in The Cancer Genome Atlas (TCGA). Differential protein expression analysis revealed a high level of agreement in the fold change of tumor versus normal tissue within cohorts before and after normalization. Furthermore, our results indicate that global quantile normalization resulted in the highest cohort rank correlation between CPTAC and TCGA for selected proteins. ConclusionsIn summary, our thorough analysis demonstrates that global quantile normalization surpasses both smooth quantile normalization and no normalization, as evidenced by its higher rank correlation across cancer cohorts between CPTAC and TCGA for selected proteins. The findings suggest that combining cohort hybrid imputation with global quantile normalization is an effective method for creating a normalized CPTAC pan-cancer protein dataset, which can facilitate the study of protein expression across different cancer types.

bioinformatics↗

Pan-cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer Therapeutics

The National Cancer Institutes Clinical Proteomic Tumor Analysis Consortium (CPTAC) provides unique opportunities for cancer target discovery using protein expression. Proteomics data from CPTAC tumor types have been primarily generated using a multiplex tandem mass tag (TMT) approach, which is designed to provide protein quantification relative to reference samples. However, relative protein expression data is suboptimal for prioritization of targets within a tissue type, which requires additional reprocessing of the original proteomics data to derive absolute quantitation estimation. We evaluated the feasibility of using differential protein analysis coupled with intensity-based absolute quantification (iBAQ) to identify tumor-enriched and highly expressed cell surface antigens, employing tandem mass tag (TMT) proteomics data from CPTAC. Absolute quantification derived from TMT proteomics data was highly correlated with that of label-free proteomics data from the CPTAC colon adenocarcinoma cohort, which contains proteomics data measured by both approaches. We validated the TMT-iBAQ approach by comparing the iBAQ value to the receptor density value of HER2 and TROP2 measured by flow cytometry in about 30 selected breast and lung cancer cell lines from the Cancer Cell Line Encyclopedia. Collections of these tumor-enriched and highly expressed cell surface antigens could serve as a valuable resource for the development of cancer therapeutics, including antibody-drug conjugates and immunotherapeutic agents.

bioinformatics↗